,paragraph,value,label,name,type,company,sent,entity,entity_type_ext,sentence,phrases,qa_temp,key,score,question,answer,GPT3 Responses
0,"For the fiscal year ended December 31, 2021 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934","December 31, 2021",['Document Period End Date'],dei_DocumentPeriodEndDate,dateItemType,bsx,"For the fiscal year ended December 31, 2021 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934","the fiscal year ended December 31, 2021",DATE,"For the fiscal year ended December 31, 2021 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 OF THE SECURITIES EXCHANGE ACT OF 1934","['SECTION OF EXCHANGE ACT', 'TRANSITION REPORT PURSUANT']","['', 0, '', '']",,0.0,,,TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 OF THE SECURITIES EXCHANGE ACT OF 1934
1,"The aggregate market value of the registrant's common stock held by non affiliates was approximately $60.6 billion based on the last reported sale price of $42.76 of the registrant's common stock on the New York Stock Exchange on June 30, 2021, the last business day of the registrant's most recently completed second fiscal quarter. (For this computation, the registrant has excluded the market value of all shares of common stock of the registrant reported as beneficially owned by executive officers, and directors of the registrant; such exclusion shall not be deemed to constitute an admission that any such person is an affiliate of the registrant.)",60.6,['Entity Public Float'],dei_EntityPublicFloat,monetaryItemType,bsx,"The aggregate market value of the registrant’s common stock held by non affiliates was approximately $60.6 billion based on the last reported sale price of $42.76 of the registrant’s common stock on the New York Stock Exchange on June 30, 2021, the last business day of the registrant’s most recently completed second fiscal quarter.",approximately $60.6 billion,MONEY,"The aggregate market value of the registrant’s common stock held by non affiliates was approximately $60.6 billion based on the last reported sale price of $42.76 of the registrant’s common stock on the New York Stock Exchange on June 30, 2021, the last business day of the registrant’s most recently completed second fiscal quarter.","['aggregate market value of registrant common stock', 'last reported sale price', 'registrant common stock on York Stock Exchange', 'last reported sale price on June', 'last business day of registrant', 'aggregate market value', 'registrant common stock', 'non affiliates', 'last sale price', 'registrant common stock']","['aggregate market value of the registrant’s common stock', 0.21167878806591034, 'What is approximately $60.6 billion ?', 'aggregate market value of the registrant’s common stock']",aggregate market value of the registrant’s common stock,0.2116787880659103,What is approximately $60.6 billion ?,aggregate market value of the registrant’s common stock,the aggregate market value of the registrant's common stock held by non affiliates
2,"The number of shares outstanding of Common Stock, $0.01 par value per share, as of January 31, 2022 was 1,426,724,712.","1,426,724,712","['Entity Common Stock, Shares Outstanding']",dei_EntityCommonStockSharesOutstanding,sharesItemType,bsx,"The number of shares outstanding of Common Stock, $0.01 par value per share, as of January 31, 2022 was 1,426,724,712.","1,426,724,712",CARDINAL,"The number of shares outstanding of Common Stock, $0.01 par value per share, as of January 31, 2022 was 1,426,724,712.","['number of outstanding shares', 'par value per share', 'number', 'outstanding shares']","['outstanding shares', 0.9299687147140503, 'how many outstanding shares ?', '1,426,724,712']",outstanding shares,0.9299687147140504,how many outstanding shares ?,"1,426,724,712",shares outstanding of Common Stock
3,"Preferred stock, $0.01 par value authorized 50,000,000 shares; issued 10,062,500 shares as of December 31, 2021 and December 31, 2020","50,000,000","['Preferred Stock, Shares Authorized', 'Preferred Stock, Shares Authorized']",us-gaap_PreferredStockSharesAuthorized,sharesItemType,bsx,"Preferred stock, $0.01 par value   authorized 50,000,000 shares; issued 10,062,500 shares as of December 31, 2021 and December 31, 2020","50,000,000",CARDINAL,"Preferred stock, $0.01 par value   authorized 50,000,000 shares; issued 10,062,500 shares as of December 31, 2021 and December 31, 2020","['Preferred stock', 'par value']","['Preferred stock', 0.8312630653381348, 'how many Preferred stock ?', '50,000,000']",Preferred stock,0.8312630653381348,how many Preferred stock ?,"50,000,000",Preferred stock authorized shares
4,"Preferred stock, $0.01 par value authorized 50,000,000 shares; issued 10,062,500 shares as of December 31, 2021 and December 31, 2020","50,000,000","['Preferred Stock, Shares Authorized', 'Preferred Stock, Shares Authorized']",us-gaap_PreferredStockSharesAuthorized,sharesItemType,bsx,"Preferred stock, $0.01 par value   authorized 50,000,000 shares; issued 10,062,500 shares as of December 31, 2021 and December 31, 2020","50,000,000",CARDINAL,"Preferred stock, $0.01 par value   authorized 50,000,000 shares; issued 10,062,500 shares as of December 31, 2021 and December 31, 2020","['Preferred stock', 'par value']","['Preferred stock', 0.8312630653381348, 'how many Preferred stock ?', '50,000,000']",Preferred stock,0.8312630653381348,how many Preferred stock ?,"50,000,000",Preferred stock shares
5,"Preferred stock, $0.01 par value authorized 50,000,000 shares; issued 10,062,500 shares as of December 31, 2021 and December 31, 2020","10,062,500","['Preferred Stock, Shares Issued']",us-gaap_PreferredStockSharesIssued,sharesItemType,bsx,"Preferred stock, $0.01 par value   authorized 50,000,000 shares; issued 10,062,500 shares as of December 31, 2021 and December 31, 2020","10,062,500",CARDINAL,"Preferred stock, $0.01 par value   authorized 50,000,000 shares; issued 10,062,500 shares as of December 31, 2021 and December 31, 2020","['Preferred stock', 'par value']","['shares', 0.5060889720916748, 'What is 10,062,500 ?', 'shares']",shares,0.5060889720916748,"What is 10,062,500 ?",shares,Preferred stock shares
6,"Preferred stock, $0.01 par value authorized 50,000,000 shares; issued 10,062,500 shares as of December 31, 2021 and December 31, 2020","10,062,500","['Preferred Stock, Shares Issued']",us-gaap_PreferredStockSharesIssued,sharesItemType,bsx,"Preferred stock, $0.01 par value   authorized 50,000,000 shares; issued 10,062,500 shares as of December 31, 2021 and December 31, 2020","10,062,500",CARDINAL,"Preferred stock, $0.01 par value   authorized 50,000,000 shares; issued 10,062,500 shares as of December 31, 2021 and December 31, 2020","['Preferred stock', 'par value']","['shares', 0.5060889720916748, 'What is 10,062,500 ?', 'shares']",shares,0.5060889720916748,"What is 10,062,500 ?",shares,Preferred stock shares
7,"Common stock, $0.01 par value authorized 2,000,000,000 shares; issued 1,688,810,052 shares as of December 31, 2021 and 1,679,911,918 shares as of December 31, 2020","2,000,000,000","['Common Stock, Shares Authorized', 'Common Stock, Shares Authorized']",us-gaap_CommonStockSharesAuthorized,sharesItemType,bsx,"Common stock, $0.01 par value   authorized 2,000,000,000 shares; issued 1,688,810,052 shares as of December 31, 2021 and 1,679,911,918 shares as of December 31, 2020","2,000,000,000",CARDINAL,"Common stock, $0.01 par value   authorized 2,000,000,000 shares; issued 1,688,810,052 shares as of December 31, 2021 and 1,679,911,918 shares as of December 31, 2020",['Common stock'],"['Common stock', 0.821918785572052, 'how many Common stock ?', '2,000,000,000']",Common stock,0.821918785572052,how many Common stock ?,"2,000,000,000",Authorized shares
8,"Common stock, $0.01 par value authorized 2,000,000,000 shares; issued 1,688,810,052 shares as of December 31, 2021 and 1,679,911,918 shares as of December 31, 2020","2,000,000,000","['Common Stock, Shares Authorized', 'Common Stock, Shares Authorized']",us-gaap_CommonStockSharesAuthorized,sharesItemType,bsx,"Common stock, $0.01 par value   authorized 2,000,000,000 shares; issued 1,688,810,052 shares as of December 31, 2021 and 1,679,911,918 shares as of December 31, 2020","2,000,000,000",CARDINAL,"Common stock, $0.01 par value   authorized 2,000,000,000 shares; issued 1,688,810,052 shares as of December 31, 2021 and 1,679,911,918 shares as of December 31, 2020",['Common stock'],"['Common stock', 0.821918785572052, 'how many Common stock ?', '2,000,000,000']",Common stock,0.821918785572052,how many Common stock ?,"2,000,000,000","Authorized shares

Entity:
1,688,810,052
Phrase: 
Issued shares as of December 31, 2021

Entity: 
1,679,911,918
Phrase: 
Issued shares as of December 31, 2020"
9,"Common stock, $0.01 par value authorized 2,000,000,000 shares; issued 1,688,810,052 shares as of December 31, 2021 and 1,679,911,918 shares as of December 31, 2020","1,688,810,052","['Common Stock, Shares, Issued']",us-gaap_CommonStockSharesIssued,sharesItemType,bsx,"Common stock, $0.01 par value   authorized 2,000,000,000 shares; issued 1,688,810,052 shares as of December 31, 2021 and 1,679,911,918 shares as of December 31, 2020","1,688,810,052",CARDINAL,"Common stock, $0.01 par value   authorized 2,000,000,000 shares; issued 1,688,810,052 shares as of December 31, 2021 and 1,679,911,918 shares as of December 31, 2020",['Common stock'],"['', 0, '', '']",,0.0,,,"Common stock shares issued December 31, 2021"
10,"Common stock, $0.01 par value authorized 2,000,000,000 shares; issued 1,688,810,052 shares as of December 31, 2021 and 1,679,911,918 shares as of December 31, 2020","1,679,911,918","['Common Stock, Shares, Issued']",us-gaap_CommonStockSharesIssued,sharesItemType,bsx,"Common stock, $0.01 par value   authorized 2,000,000,000 shares; issued 1,688,810,052 shares as of December 31, 2021 and 1,679,911,918 shares as of December 31, 2020","1,679,911,918",CARDINAL,"Common stock, $0.01 par value   authorized 2,000,000,000 shares; issued 1,688,810,052 shares as of December 31, 2021 and 1,679,911,918 shares as of December 31, 2020",['Common stock'],"['shares', 0.5880967974662781, 'What is 1,679,911,918 ?', 'shares']",shares,0.5880967974662781,"What is 1,679,911,918 ?",shares,"Common stock shares issued as of December 31, 2020"
11,"Treasury stock, at cost 263,289,848 shares as of December 31, 2021 and December 31, 2020","263,289,848","['Treasury Stock, Shares']",us-gaap_TreasuryStockShares,sharesItemType,bsx,"Treasury stock, at cost   263,289,848 shares as of December 31, 2021 and December 31, 2020","263,289,848",CARDINAL,"Treasury stock, at cost   263,289,848 shares as of December 31, 2021 and December 31, 2020","['Treasury stock at shares', 'shares']","['Treasury stock at shares', 0.9799051284790039, 'how many Treasury stock at shares ?', '263,289,848']",Treasury stock at shares,0.979905128479004,how many Treasury stock at shares ?,"263,289,848",Treasury stock
12,"Treasury stock, at cost 263,289,848 shares as of December 31, 2021 and December 31, 2020","263,289,848","['Treasury Stock, Shares']",us-gaap_TreasuryStockShares,sharesItemType,bsx,"Treasury stock, at cost   263,289,848 shares as of December 31, 2021 and December 31, 2020","263,289,848",CARDINAL,"Treasury stock, at cost   263,289,848 shares as of December 31, 2021 and December 31, 2020","['Treasury stock at shares', 'shares']","['Treasury stock at shares', 0.9799051284790039, 'how many Treasury stock at shares ?', '263,289,848']",Treasury stock at shares,0.979905128479004,how many Treasury stock at shares ?,"263,289,848",Treasury stock
13,"We state inventories at the lower of first in, first out cost or net realizable value. We utilize a standard costing system, capitalizing variances between estimated and actual production costs during periods of normal production, and amortize to Cost of products sold over inventory turns. We expense manufacturing variances during periods of abnormal production, or less than 75 percent of manufacturing capacity. During 2020, we recorded $149 million of abnormal manufacturing variances attributable to lower production levels resulting from the COVID 19 pandemic and lower than forecasted demand for our products. We did not record any abnormal production variances during the years ended December 31, 2021 or 2019.",149,['Production Related Impairments or Charges'],us-gaap_ProductionRelatedImpairmentsOrCharges,monetaryItemType,bsx,"During 2020, we recorded $149 million of abnormal manufacturing variances attributable to lower production levels resulting from the COVID 19 pandemic and lower than forecasted demand for our products.",$149 million,MONEY,"During 2020, we recorded $149 million of abnormal manufacturing variances attributable to lower production levels resulting from the COVID 19 pandemic and lower than forecasted demand for our products.","['forecasted demand for products', 'abnormal manufacturing variances', 'production levels']","['abnormal manufacturing variances', 0.6873335242271423, 'What is $149 million ?', 'abnormal manufacturing variances']",abnormal manufacturing variances,0.6873335242271423,What is $149 million ?,abnormal manufacturing variances,Abnormal manufacturing variances
14,"We generally do not bill customers for shipping and handling of our products. We treat shipping costs incurred after a customer obtains control of the good as a fulfillment cost and record in Selling, general and administrative expenses within our consolidated statements of operations. Shipping costs were $194 million in 2021, $146 million in 2020 and $144 million in 2019.",194,"['Selling, general and administrative expenses']",us-gaap_SellingGeneralAndAdministrativeExpense,monetaryItemType,bsx,"Shipping costs were $194 million in 2021, $146 million in 2020 and $144 million in 2019.",$194 million,MONEY,"Shipping costs were $194 million in 2021, $146 million in 2020 and $144 million in 2019.",['Shipping costs'],"['Shipping costs', 0.7035617828369141, 'What is $194 million ?', 'Shipping costs']",Shipping costs,0.7035617828369141,What is $194 million ?,Shipping costs,Shipping costs in 2021
15,"We generally do not bill customers for shipping and handling of our products. We treat shipping costs incurred after a customer obtains control of the good as a fulfillment cost and record in Selling, general and administrative expenses within our consolidated statements of operations. Shipping costs were $194 million in 2021, $146 million in 2020 and $144 million in 2019.",146,"['Selling, general and administrative expenses']",us-gaap_SellingGeneralAndAdministrativeExpense,monetaryItemType,bsx,"Shipping costs were $194 million in 2021, $146 million in 2020 and $144 million in 2019.",$146 million,MONEY,"Shipping costs were $194 million in 2021, $146 million in 2020 and $144 million in 2019.",['Shipping costs'],"['', 0, '', '']",,0.0,,,shipping costs in 2020
16,"We generally do not bill customers for shipping and handling of our products. We treat shipping costs incurred after a customer obtains control of the good as a fulfillment cost and record in Selling, general and administrative expenses within our consolidated statements of operations. Shipping costs were $194 million in 2021, $146 million in 2020 and $144 million in 2019.",144,"['Selling, general and administrative expenses']",us-gaap_SellingGeneralAndAdministrativeExpense,monetaryItemType,bsx,"Shipping costs were $194 million in 2021, $146 million in 2020 and $144 million in 2019.",$144 million,MONEY,"Shipping costs were $194 million in 2021, $146 million in 2020 and $144 million in 2019.",['Shipping costs'],"['', 0, '', '']",,0.0,,,Shipping costs in 2019
17,"On February 14, 2022, we completed our acquisition of Baylis Medical Company Inc. (Baylis Medical), a privately held company which has developed the radiofrequency (RF) NRG™ and VersaCross™ Transseptal Platforms as well as a family of guidewires, sheaths and dilators used to support left heart access, which will expand our electrophysiology and structural heart product portfolios. The transaction consisted of an upfront cash payment using cash on hand of $1.750 billion subject to closing adjustments. We plan to integrate the Baylis Medical business into our Electrophysiology division, supported by our structural heart sales force.",1.750,"['Payments to Acquire Businesses, Gross']",us-gaap_PaymentsToAcquireBusinessesGross,monetaryItemType,bsx,The transaction consisted of an upfront cash payment using cash on hand of $1.750 billion subject to closing adjustments.,$1.750 billion,MONEY,The transaction consisted of an upfront cash payment using cash on hand of $1.750 billion subject to closing adjustments.,"['hand of subject', 'upfront cash payment', 'closing adjustments']","['upfront cash payment', 0.4788208603858948, 'what is upfront cash payment ?', '$1.750 billion']",upfront cash payment,0.4788208603858948,what is upfront cash payment ?,$1.750 billion,Upfront cash payment
18,"On March 1, 2021, we completed our acquisition of the remaining shares of Preventice Solutions, Inc. (Preventice), a privately held company which offers a full portfolio of mobile cardiac health solutions and services, ranging from ambulatory cardiac monitors, to cardiac event monitors and mobile cardiac telemetry. The transaction consisted of an upfront cash payment of $925 million and up to an additional $300 million in a potential commercial milestone payment. We had been an investor in Preventice since 2015 and held an equity stake of approximately 22 percent immediately prior to the acquisition date. We remeasured the fair value of our previously held investment based on the allocation of the purchase price according to priority of equity interests, which resulted in a $196 million gain recognized within Other, net. The transaction price for the remaining stake consisted of an upfront cash payment of $706 million, net of cash acquired, and up to approximately $230 million in future milestone payments. The Preventice business is being managed by our Cardiac Rhythm Management division.",925,"['Business Combination, Consideration Transferred, Including Equity Interest in Acquiree Held Prior to Combination']",us-gaap_BusinessCombinationConsiderationTransferredIncludingEquityInterestInAcquireeHeldPriorToCombination1,monetaryItemType,bsx,The transaction consisted of an upfront cash payment of $925 million and up to an additional $300 million in a potential commercial milestone payment.,$925 million,MONEY,The transaction consisted of an upfront cash payment of $925 million and up to an additional $300 million in a potential commercial milestone payment.,"['upfront cash payment', 'upfront cash payment', 'potential milestone payment']","['upfront cash payment', 0.9832380414009094, 'what is upfront cash payment ?', '$925 million']",upfront cash payment,0.9832380414009094,what is upfront cash payment ?,$925 million,Upfront cash payment
19,"On March 1, 2021, we completed our acquisition of the remaining shares of Preventice Solutions, Inc. (Preventice), a privately held company which offers a full portfolio of mobile cardiac health solutions and services, ranging from ambulatory cardiac monitors, to cardiac event monitors and mobile cardiac telemetry. The transaction consisted of an upfront cash payment of $925 million and up to an additional $300 million in a potential commercial milestone payment. We had been an investor in Preventice since 2015 and held an equity stake of approximately 22 percent immediately prior to the acquisition date. We remeasured the fair value of our previously held investment based on the allocation of the purchase price according to priority of equity interests, which resulted in a $196 million gain recognized within Other, net. The transaction price for the remaining stake consisted of an upfront cash payment of $706 million, net of cash acquired, and up to approximately $230 million in future milestone payments. The Preventice business is being managed by our Cardiac Rhythm Management division.",300,"['Business combination, contingent consideration arrangements, range of outcomes, value, high, including prior interest']",bsx_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHighIncludingPriorInterest,monetaryItemType,bsx,The transaction consisted of an upfront cash payment of $925 million and up to an additional $300 million in a potential commercial milestone payment.,an additional $300 million,MONEY,The transaction consisted of an upfront cash payment of $925 million and up to an additional $300 million in a potential commercial milestone payment.,"['upfront cash payment', 'upfront cash payment', 'potential milestone payment']","['a potential commercial milestone payment', 0.32953181862831116, 'What is an additional $300 million ?', 'a potential commercial milestone payment']",a potential commercial milestone payment,0.3295318186283111,What is an additional $300 million ?,a potential commercial milestone payment,commercial milestone payment
20,"On March 1, 2021, we completed our acquisition of the remaining shares of Preventice Solutions, Inc. (Preventice), a privately held company which offers a full portfolio of mobile cardiac health solutions and services, ranging from ambulatory cardiac monitors, to cardiac event monitors and mobile cardiac telemetry. The transaction consisted of an upfront cash payment of $925 million and up to an additional $300 million in a potential commercial milestone payment. We had been an investor in Preventice since 2015 and held an equity stake of approximately 22 percent immediately prior to the acquisition date. We remeasured the fair value of our previously held investment based on the allocation of the purchase price according to priority of equity interests, which resulted in a $196 million gain recognized within Other, net. The transaction price for the remaining stake consisted of an upfront cash payment of $706 million, net of cash acquired, and up to approximately $230 million in future milestone payments. The Preventice business is being managed by our Cardiac Rhythm Management division.",196,"['Business Combination, Step Acquisition, Equity Interest in Acquiree, Remeasurement Gain']",us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain,monetaryItemType,bsx,"We remeasured the fair value of our previously held investment based on the allocation of the purchase price according to priority of equity interests, which resulted in a $196 million gain recognized within Other, net.",$196 million,MONEY,"We remeasured the fair value of our previously held investment based on the allocation of the purchase price according to priority of equity interests, which resulted in a $196 million gain recognized within Other, net.","['fair value of held investment', 'allocation of purchase price', 'priority of equity interests', 'fair value', 'purchase price', 'equity interests', 'Other net']","['Other net', 0.4580364525318146, 'what is Other net ?', '$196 million gain']",Other net,0.4580364525318146,what is Other net ?,$196 million gain,Gain recognized within Other
21,"On March 1, 2021, we completed our acquisition of the remaining shares of Preventice Solutions, Inc. (Preventice), a privately held company which offers a full portfolio of mobile cardiac health solutions and services, ranging from ambulatory cardiac monitors, to cardiac event monitors and mobile cardiac telemetry. The transaction consisted of an upfront cash payment of $925 million and up to an additional $300 million in a potential commercial milestone payment. We had been an investor in Preventice since 2015 and held an equity stake of approximately 22 percent immediately prior to the acquisition date. We remeasured the fair value of our previously held investment based on the allocation of the purchase price according to priority of equity interests, which resulted in a $196 million gain recognized within Other, net. The transaction price for the remaining stake consisted of an upfront cash payment of $706 million, net of cash acquired, and up to approximately $230 million in future milestone payments. The Preventice business is being managed by our Cardiac Rhythm Management division.",706,"['Payments to Acquire Businesses, Net of Cash Acquired']",us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired,monetaryItemType,bsx,"The transaction price for the remaining stake consisted of an upfront cash payment of $706 million, net of cash acquired, and up to approximately $230 million in future milestone payments.",$706 million,MONEY,"The transaction price for the remaining stake consisted of an upfront cash payment of $706 million, net of cash acquired, and up to approximately $230 million in future milestone payments.","['transaction price for remaining stake', 'upfront cash payment', 'net of cash', 'transaction price', 'upfront cash payment', 'future milestone payments']","['upfront cash payment', 0.9726234078407288, 'what is upfront cash payment ?', '$706 million']",upfront cash payment,0.9726234078407288,what is upfront cash payment ?,$706 million,upfront cash payment
22,"On March 1, 2021, we completed our acquisition of the remaining shares of Preventice Solutions, Inc. (Preventice), a privately held company which offers a full portfolio of mobile cardiac health solutions and services, ranging from ambulatory cardiac monitors, to cardiac event monitors and mobile cardiac telemetry. The transaction consisted of an upfront cash payment of $925 million and up to an additional $300 million in a potential commercial milestone payment. We had been an investor in Preventice since 2015 and held an equity stake of approximately 22 percent immediately prior to the acquisition date. We remeasured the fair value of our previously held investment based on the allocation of the purchase price according to priority of equity interests, which resulted in a $196 million gain recognized within Other, net. The transaction price for the remaining stake consisted of an upfront cash payment of $706 million, net of cash acquired, and up to approximately $230 million in future milestone payments. The Preventice business is being managed by our Cardiac Rhythm Management division.",230,"['Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High']",us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh,monetaryItemType,bsx,"The transaction price for the remaining stake consisted of an upfront cash payment of $706 million, net of cash acquired, and up to approximately $230 million in future milestone payments.",approximately $230 million,MONEY,"The transaction price for the remaining stake consisted of an upfront cash payment of $706 million, net of cash acquired, and up to approximately $230 million in future milestone payments.","['transaction price for remaining stake', 'upfront cash payment', 'net of cash', 'transaction price', 'upfront cash payment', 'future milestone payments']","['milestone payments', 0.47658485174179077, 'What is approximately $230 million ?', 'milestone payments']",milestone payments,0.4765848517417907,What is approximately $230 million ?,milestone payments,future milestone payments
23,"On August 6, 2021, we completed our acquisition of the remaining shares of Farapulse, Inc. (Farapulse), a privately held company that has developed a non thermal ablation system for the treatment of atrial fibrillation (AF) and other cardiac arrhythmias. The transaction consisted of an upfront cash payment of $450 million, up to $125 million upon achievement of certain clinical and regulatory milestones and additional revenue based payments over the next three years. We had been an investor in Farapulse since 2014 and held an equity stake of approximately 27 percent immediately prior to the acquisition date. We remeasured the fair value of our previously held investment based on the allocation of the purchase price according to priority of equity interests which resulted in a $222 million gain recognized within Other, net. The transaction price for the remaining stake consisted of an upfront cash payment of $268 million, net of cash acquired, and up to approximately $92 million in future milestone payments. The Farapulse business is being integrated into our Electrophysiology division.",450,"['Business Combination, Consideration Transferred, Including Equity Interest in Acquiree Held Prior to Combination']",us-gaap_BusinessCombinationConsiderationTransferredIncludingEquityInterestInAcquireeHeldPriorToCombination1,monetaryItemType,bsx,"The transaction consisted of an upfront cash payment of $450 million, up to $125 million upon achievement of certain clinical and regulatory milestones and additional revenue based payments over the next three years.",$450 million,MONEY,"The transaction consisted of an upfront cash payment of $450 million, up to $125 million upon achievement of certain clinical and regulatory milestones and additional revenue based payments over the next three years.","['upfront cash payment', 'achievement of certain clinical milestones', 'upfront cash payment', 'certain clinical milestones']","['upfront cash payment', 0.9701268672943115, 'what is upfront cash payment ?', '$450 million']",upfront cash payment,0.9701268672943116,what is upfront cash payment ?,$450 million,Upfront cash payment
24,"On August 6, 2021, we completed our acquisition of the remaining shares of Farapulse, Inc. (Farapulse), a privately held company that has developed a non thermal ablation system for the treatment of atrial fibrillation (AF) and other cardiac arrhythmias. The transaction consisted of an upfront cash payment of $450 million, up to $125 million upon achievement of certain clinical and regulatory milestones and additional revenue based payments over the next three years. We had been an investor in Farapulse since 2014 and held an equity stake of approximately 27 percent immediately prior to the acquisition date. We remeasured the fair value of our previously held investment based on the allocation of the purchase price according to priority of equity interests which resulted in a $222 million gain recognized within Other, net. The transaction price for the remaining stake consisted of an upfront cash payment of $268 million, net of cash acquired, and up to approximately $92 million in future milestone payments. The Farapulse business is being integrated into our Electrophysiology division.",125,"['Business combination, contingent consideration arrangements, range of outcomes, value, high, including prior interest']",bsx_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHighIncludingPriorInterest,monetaryItemType,bsx,"The transaction consisted of an upfront cash payment of $450 million, up to $125 million upon achievement of certain clinical and regulatory milestones and additional revenue based payments over the next three years.",up to $125 million,MONEY,"The transaction consisted of an upfront cash payment of $450 million, up to $125 million upon achievement of certain clinical and regulatory milestones and additional revenue based payments over the next three years.","['upfront cash payment', 'achievement of certain clinical milestones', 'upfront cash payment', 'certain clinical milestones']","['achievement of certain clinical milestones', 0.14208145439624786, 'what is achievement of certain clinical milestones ?', 'up to $125 million']",achievement of certain clinical milestones,0.1420814543962478,what is achievement of certain clinical milestones ?,up to $125 million,clinical and regulatory milestones
25,"On August 6, 2021, we completed our acquisition of the remaining shares of Farapulse, Inc. (Farapulse), a privately held company that has developed a non thermal ablation system for the treatment of atrial fibrillation (AF) and other cardiac arrhythmias. The transaction consisted of an upfront cash payment of $450 million, up to $125 million upon achievement of certain clinical and regulatory milestones and additional revenue based payments over the next three years. We had been an investor in Farapulse since 2014 and held an equity stake of approximately 27 percent immediately prior to the acquisition date. We remeasured the fair value of our previously held investment based on the allocation of the purchase price according to priority of equity interests which resulted in a $222 million gain recognized within Other, net. The transaction price for the remaining stake consisted of an upfront cash payment of $268 million, net of cash acquired, and up to approximately $92 million in future milestone payments. The Farapulse business is being integrated into our Electrophysiology division.",three years,"['Business Combination, Consideration Transferred, Additional Revenue Payment, period [Line Items]']",bsx_BusinessCombinationConsiderationTransferredAdditionalRevenuePaymentPeriod,durationItemType,bsx,"The transaction consisted of an upfront cash payment of $450 million, up to $125 million upon achievement of certain clinical and regulatory milestones and additional revenue based payments over the next three years.",the next three years,DATE,"The transaction consisted of an upfront cash payment of $450 million, up to $125 million upon achievement of certain clinical and regulatory milestones and additional revenue based payments over the next three years.","['upfront cash payment', 'achievement of certain clinical milestones', 'upfront cash payment', 'certain clinical milestones']","['revenue based payments', 0.1284082978963852, 'What is the next three years ?', 'revenue based payments']",revenue based payments,0.1284082978963852,What is the next three years ?,revenue based payments,clinical and regulatory milestones
26,"On August 6, 2021, we completed our acquisition of the remaining shares of Farapulse, Inc. (Farapulse), a privately held company that has developed a non thermal ablation system for the treatment of atrial fibrillation (AF) and other cardiac arrhythmias. The transaction consisted of an upfront cash payment of $450 million, up to $125 million upon achievement of certain clinical and regulatory milestones and additional revenue based payments over the next three years. We had been an investor in Farapulse since 2014 and held an equity stake of approximately 27 percent immediately prior to the acquisition date. We remeasured the fair value of our previously held investment based on the allocation of the purchase price according to priority of equity interests which resulted in a $222 million gain recognized within Other, net. The transaction price for the remaining stake consisted of an upfront cash payment of $268 million, net of cash acquired, and up to approximately $92 million in future milestone payments. The Farapulse business is being integrated into our Electrophysiology division.",222,"['Business Combination, Step Acquisition, Equity Interest in Acquiree, Remeasurement Gain']",us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain,monetaryItemType,bsx,"We remeasured the fair value of our previously held investment based on the allocation of the purchase price according to priority of equity interests which resulted in a $222 million gain recognized within Other, net.",$222 million,MONEY,"We remeasured the fair value of our previously held investment based on the allocation of the purchase price according to priority of equity interests which resulted in a $222 million gain recognized within Other, net.","['fair value of held investment', 'allocation of purchase price', 'priority of equity interests', 'fair value', 'purchase price', 'equity interests', 'Other net']","['Other net', 0.5669286847114563, 'what is Other net ?', '$222 million gain']",Other net,0.5669286847114563,what is Other net ?,$222 million gain,"Gain recognized within Other, net"
27,"On August 6, 2021, we completed our acquisition of the remaining shares of Farapulse, Inc. (Farapulse), a privately held company that has developed a non thermal ablation system for the treatment of atrial fibrillation (AF) and other cardiac arrhythmias. The transaction consisted of an upfront cash payment of $450 million, up to $125 million upon achievement of certain clinical and regulatory milestones and additional revenue based payments over the next three years. We had been an investor in Farapulse since 2014 and held an equity stake of approximately 27 percent immediately prior to the acquisition date. We remeasured the fair value of our previously held investment based on the allocation of the purchase price according to priority of equity interests which resulted in a $222 million gain recognized within Other, net. The transaction price for the remaining stake consisted of an upfront cash payment of $268 million, net of cash acquired, and up to approximately $92 million in future milestone payments. The Farapulse business is being integrated into our Electrophysiology division.",268,"['Payments to Acquire Businesses, Net of Cash Acquired']",us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired,monetaryItemType,bsx,"The transaction price for the remaining stake consisted of an upfront cash payment of $268 million, net of cash acquired, and up to approximately $92 million in future milestone payments.",$268 million,MONEY,"The transaction price for the remaining stake consisted of an upfront cash payment of $268 million, net of cash acquired, and up to approximately $92 million in future milestone payments.","['transaction price for remaining stake', 'upfront cash payment', 'net of cash', 'transaction price', 'upfront cash payment', 'future milestone payments']","['upfront cash payment', 0.9762248992919922, 'what is upfront cash payment ?', '$268 million']",upfront cash payment,0.9762248992919922,what is upfront cash payment ?,$268 million,upfront cash payment
28,"On August 6, 2021, we completed our acquisition of the remaining shares of Farapulse, Inc. (Farapulse), a privately held company that has developed a non thermal ablation system for the treatment of atrial fibrillation (AF) and other cardiac arrhythmias. The transaction consisted of an upfront cash payment of $450 million, up to $125 million upon achievement of certain clinical and regulatory milestones and additional revenue based payments over the next three years. We had been an investor in Farapulse since 2014 and held an equity stake of approximately 27 percent immediately prior to the acquisition date. We remeasured the fair value of our previously held investment based on the allocation of the purchase price according to priority of equity interests which resulted in a $222 million gain recognized within Other, net. The transaction price for the remaining stake consisted of an upfront cash payment of $268 million, net of cash acquired, and up to approximately $92 million in future milestone payments. The Farapulse business is being integrated into our Electrophysiology division.",92,"['Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High']",us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh,monetaryItemType,bsx,"The transaction price for the remaining stake consisted of an upfront cash payment of $268 million, net of cash acquired, and up to approximately $92 million in future milestone payments.",approximately $92 million,MONEY,"The transaction price for the remaining stake consisted of an upfront cash payment of $268 million, net of cash acquired, and up to approximately $92 million in future milestone payments.","['transaction price for remaining stake', 'upfront cash payment', 'net of cash', 'transaction price', 'upfront cash payment', 'future milestone payments']","['milestone payments', 0.4859970808029175, 'What is approximately $92 million ?', 'milestone payments']",milestone payments,0.4859970808029175,What is approximately $92 million ?,milestone payments,future milestone payments
29,"On September 1, 2021, we completed our acquisition of the global surgical business of Lumenis LTD. (Lumenis), a privately held company that develops and commercializes energy based medical solutions, including innovative laser systems, fibers and accessories used for urology and otolaryngology procedures. The transaction consisted of an upfront cash payment of $1.032 billion, net of cash acquired. The Lumenis business is being integrated into our Urology and Pelvic Health division.",1.032,"['Payments to Acquire Businesses, Net of Cash Acquired']",us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired,monetaryItemType,bsx,"The transaction consisted of an upfront cash payment of $1.032 billion, net of cash acquired.",$1.032 billion,MONEY,"The transaction consisted of an upfront cash payment of $1.032 billion, net of cash acquired.","['upfront cash payment', 'net of cash', 'upfront cash payment']","['upfront cash payment', 0.9652261137962341, 'what is upfront cash payment ?', '$1.032 billion']",upfront cash payment,0.965226113796234,what is upfront cash payment ?,$1.032 billion,Upfront cash payment
30,"On November 8, 2021, we completed our acquisition of the remaining shares of Devoro Medical, Inc. (Devoro Medical), a privately held company which has developed the WOLF Thrombectomy® Platform, a non console and lytic free platform designed to rapidly capture and extract blood clots in arterial, venous and pulmonary embolism procedures. The transaction consisted of an upfront cash payment of $320 million and up to $80 million upon achievement of certain clinical and regulatory milestones. We had been an investor in Devoro Medical since 2019 and held an equity stake of approximately 16 percent. We remeasured the fair value of our previously held investment based on the allocation of the purchase price according to priority of equity interests which resulted in a $57 million gain recognized within Other, net. The transaction price for the remaining stake consisted of an upfront cash payment of $251 million, net of cash acquired, and up to approximately $67 million in future milestone payments. The Devoro Medical business is being integrated into our Peripheral Interventions division.",320,"['Business Combination, Consideration Transferred, Including Equity Interest in Acquiree Held Prior to Combination']",us-gaap_BusinessCombinationConsiderationTransferredIncludingEquityInterestInAcquireeHeldPriorToCombination1,monetaryItemType,bsx,The transaction consisted of an upfront cash payment of $320 million and up to $80 million upon achievement of certain clinical and regulatory milestones.,$320 million,MONEY,The transaction consisted of an upfront cash payment of $320 million and up to $80 million upon achievement of certain clinical and regulatory milestones.,"['upfront cash payment', 'achievement of certain clinical milestones', 'upfront cash payment', 'certain clinical milestones']","['upfront cash payment', 0.9744154214859009, 'what is upfront cash payment ?', '$320 million']",upfront cash payment,0.9744154214859008,what is upfront cash payment ?,$320 million,Upfront cash payment
31,"On November 8, 2021, we completed our acquisition of the remaining shares of Devoro Medical, Inc. (Devoro Medical), a privately held company which has developed the WOLF Thrombectomy® Platform, a non console and lytic free platform designed to rapidly capture and extract blood clots in arterial, venous and pulmonary embolism procedures. The transaction consisted of an upfront cash payment of $320 million and up to $80 million upon achievement of certain clinical and regulatory milestones. We had been an investor in Devoro Medical since 2019 and held an equity stake of approximately 16 percent. We remeasured the fair value of our previously held investment based on the allocation of the purchase price according to priority of equity interests which resulted in a $57 million gain recognized within Other, net. The transaction price for the remaining stake consisted of an upfront cash payment of $251 million, net of cash acquired, and up to approximately $67 million in future milestone payments. The Devoro Medical business is being integrated into our Peripheral Interventions division.",80,"['Business combination, contingent consideration arrangements, range of outcomes, value, high, including prior interest']",bsx_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHighIncludingPriorInterest,monetaryItemType,bsx,The transaction consisted of an upfront cash payment of $320 million and up to $80 million upon achievement of certain clinical and regulatory milestones.,up to $80 million,MONEY,The transaction consisted of an upfront cash payment of $320 million and up to $80 million upon achievement of certain clinical and regulatory milestones.,"['upfront cash payment', 'achievement of certain clinical milestones', 'upfront cash payment', 'certain clinical milestones']","['achievement of certain clinical milestones', 0.5058713555335999, 'what is achievement of certain clinical milestones ?', 'up to $80 million']",achievement of certain clinical milestones,0.5058713555335999,what is achievement of certain clinical milestones ?,up to $80 million,clinical and regulatory milestones
32,"On November 8, 2021, we completed our acquisition of the remaining shares of Devoro Medical, Inc. (Devoro Medical), a privately held company which has developed the WOLF Thrombectomy® Platform, a non console and lytic free platform designed to rapidly capture and extract blood clots in arterial, venous and pulmonary embolism procedures. The transaction consisted of an upfront cash payment of $320 million and up to $80 million upon achievement of certain clinical and regulatory milestones. We had been an investor in Devoro Medical since 2019 and held an equity stake of approximately 16 percent. We remeasured the fair value of our previously held investment based on the allocation of the purchase price according to priority of equity interests which resulted in a $57 million gain recognized within Other, net. The transaction price for the remaining stake consisted of an upfront cash payment of $251 million, net of cash acquired, and up to approximately $67 million in future milestone payments. The Devoro Medical business is being integrated into our Peripheral Interventions division.",57,"['Business Combination, Step Acquisition, Equity Interest in Acquiree, Remeasurement Gain']",us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain,monetaryItemType,bsx,"We remeasured the fair value of our previously held investment based on the allocation of the purchase price according to priority of equity interests which resulted in a $57 million gain recognized within Other, net.",$57 million,MONEY,"We remeasured the fair value of our previously held investment based on the allocation of the purchase price according to priority of equity interests which resulted in a $57 million gain recognized within Other, net.","['fair value of held investment', 'allocation of purchase price', 'priority of equity interests', 'fair value', 'purchase price', 'equity interests', 'Other net']","['Other net', 0.5518304705619812, 'what is Other net ?', '$57 million gain']",Other net,0.5518304705619812,what is Other net ?,$57 million gain,Gain recognized within Other
33,"On November 8, 2021, we completed our acquisition of the remaining shares of Devoro Medical, Inc. (Devoro Medical), a privately held company which has developed the WOLF Thrombectomy® Platform, a non console and lytic free platform designed to rapidly capture and extract blood clots in arterial, venous and pulmonary embolism procedures. The transaction consisted of an upfront cash payment of $320 million and up to $80 million upon achievement of certain clinical and regulatory milestones. We had been an investor in Devoro Medical since 2019 and held an equity stake of approximately 16 percent. We remeasured the fair value of our previously held investment based on the allocation of the purchase price according to priority of equity interests which resulted in a $57 million gain recognized within Other, net. The transaction price for the remaining stake consisted of an upfront cash payment of $251 million, net of cash acquired, and up to approximately $67 million in future milestone payments. The Devoro Medical business is being integrated into our Peripheral Interventions division.",251,"['Payments to Acquire Businesses, Net of Cash Acquired']",us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired,monetaryItemType,bsx,"The transaction price for the remaining stake consisted of an upfront cash payment of $251 million, net of cash acquired, and up to approximately $67 million in future milestone payments.",$251 million,MONEY,"The transaction price for the remaining stake consisted of an upfront cash payment of $251 million, net of cash acquired, and up to approximately $67 million in future milestone payments.","['transaction price for remaining stake', 'upfront cash payment', 'net of cash', 'transaction price', 'upfront cash payment', 'future milestone payments']","['upfront cash payment', 0.9692445993423462, 'what is upfront cash payment ?', '$251 million']",upfront cash payment,0.9692445993423462,what is upfront cash payment ?,$251 million,Upfront cash payment
34,"On November 8, 2021, we completed our acquisition of the remaining shares of Devoro Medical, Inc. (Devoro Medical), a privately held company which has developed the WOLF Thrombectomy® Platform, a non console and lytic free platform designed to rapidly capture and extract blood clots in arterial, venous and pulmonary embolism procedures. The transaction consisted of an upfront cash payment of $320 million and up to $80 million upon achievement of certain clinical and regulatory milestones. We had been an investor in Devoro Medical since 2019 and held an equity stake of approximately 16 percent. We remeasured the fair value of our previously held investment based on the allocation of the purchase price according to priority of equity interests which resulted in a $57 million gain recognized within Other, net. The transaction price for the remaining stake consisted of an upfront cash payment of $251 million, net of cash acquired, and up to approximately $67 million in future milestone payments. The Devoro Medical business is being integrated into our Peripheral Interventions division.",67,"['Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High']",us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh,monetaryItemType,bsx,"The transaction price for the remaining stake consisted of an upfront cash payment of $251 million, net of cash acquired, and up to approximately $67 million in future milestone payments.",approximately $67 million,MONEY,"The transaction price for the remaining stake consisted of an upfront cash payment of $251 million, net of cash acquired, and up to approximately $67 million in future milestone payments.","['transaction price for remaining stake', 'upfront cash payment', 'net of cash', 'transaction price', 'upfront cash payment', 'future milestone payments']","['milestone payments', 0.5416720509529114, 'What is approximately $67 million ?', 'milestone payments']",milestone payments,0.5416720509529114,What is approximately $67 million ?,milestone payments,future milestone payments
35,"On March 1, 2021, we completed the divestiture of the Specialty Pharmaceuticals business to Stark International Lux S.A.R.L., and SERB SAS, affiliates of SERB, a European specialty pharmaceutical group, for a purchase price of approximately $800 million. The agreement included the transfer of five facilities and approximately 280 employees globally.",800,"['Disposal Group, Including Discontinued Operation, Consideration']",us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration,monetaryItemType,bsx,"On March 1, 2021, we completed the divestiture of the Specialty Pharmaceuticals business to Stark International Lux S.A.R.L., and SERB SAS, affiliates of SERB, a European specialty pharmaceutical group, for a purchase price of approximately $800 million.",approximately $800 million,MONEY,"On March 1, 2021, we completed the divestiture of the Specialty Pharmaceuticals business to Stark International Lux S.A.R.L., and SERB SAS, affiliates of SERB, a European specialty pharmaceutical group, for a purchase price of approximately $800 million.","['divestiture of Pharmaceuticals business', 'divestiture to Stark International Lux S.A.R.L.', 'affiliates of SERB', 'purchase price', 'Pharmaceuticals business', 'Stark International Lux S.A.R.L.', 'purchase price']","['purchase price', 0.8466163873672485, 'What is approximately $800 million ?', 'purchase price']",purchase price,0.8466163873672485,What is approximately $800 million ?,purchase price,Specialty Pharmaceuticals business
36,"On March 1, 2021, we completed the divestiture of the Specialty Pharmaceuticals business to Stark International Lux S.A.R.L., and SERB SAS, affiliates of SERB, a European specialty pharmaceutical group, for a purchase price of approximately $800 million. The agreement included the transfer of five facilities and approximately 280 employees globally.",five,"['Divestiture, agreement, transfer of facilities']",bsx_DivestitureAgreementTransferOfFacilities,integerItemType,bsx,The agreement included the transfer of five facilities and approximately 280 employees globally.,five,CARDINAL,The agreement included the transfer of five facilities and approximately 280 employees globally.,['transfer of facilities'],"['transfer of facilities', 0.9230533838272095, 'how many transfer of facilities ?', 'five']",transfer of facilities,0.9230533838272096,how many transfer of facilities ?,five,facilities
37,"On March 1, 2021, we completed the divestiture of the Specialty Pharmaceuticals business to Stark International Lux S.A.R.L., and SERB SAS, affiliates of SERB, a European specialty pharmaceutical group, for a purchase price of approximately $800 million. The agreement included the transfer of five facilities and approximately 280 employees globally.",280,"['Divestiture, agreement, transfer of global employees']",bsx_DivestitureAgreementTransferOfGlobalEmployees,integerItemType,bsx,The agreement included the transfer of five facilities and approximately 280 employees globally.,approximately 280,CARDINAL,The agreement included the transfer of five facilities and approximately 280 employees globally.,['transfer of facilities'],"['employees globally', 0.6486871242523193, 'What is approximately 280 ?', 'employees globally']",employees globally,0.6486871242523193,What is approximately 280 ?,employees globally,employees globally
38,"In addition to the Interventional Medicine product lines, the BTG portfolio also included the Specialty Pharmaceuticals business, comprised of acute care antidotes to treat overexposure to certain medications and toxins. On March 1, 2021, we completed the divestiture of Specialty Pharmaceuticals for a purchase price of approximately $800 million. Refer to Note C-Assets and Liabilities Held for Sale for additional information.",800,"['Disposal Group, Including Discontinued Operation, Consideration']",us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration,monetaryItemType,bsx,"On March 1, 2021, we completed the divestiture of Specialty Pharmaceuticals for a purchase price of approximately $800 million.",approximately $800 million,MONEY,"On March 1, 2021, we completed the divestiture of Specialty Pharmaceuticals for a purchase price of approximately $800 million.","['divestiture of Specialty Pharmaceuticals', 'purchase price', 'purchase price']","['divestiture of Specialty Pharmaceuticals', 0.3251383304595947, 'what is divestiture of Specialty Pharmaceuticals ?', 'purchase price of approximately $800 million']",divestiture of Specialty Pharmaceuticals,0.3251383304595947,what is divestiture of Specialty Pharmaceuticals ?,purchase price of approximately $800 million,Specialty Pharmaceuticals divestiture
39,"The BTG portfolio further included a licensing portfolio (Licensing arrangements) that generated net royalties related to BTG intellectual property and product license agreements. In connection with the acquisition, we acquired rights to future royalties associated with the Zytiga™ Drug used to treat certain forms of prostate cancer. In the fourth quarter of 2019, we sold our rights to these royalties for $256 million in cash, included in Proceeds from royalty rights transfer in our consolidated statements of cash flows. Refer to Note E-Hedging Activities and Fair Value Measurements for additional information.",256,['Proceeds from royalty rights transfer'],bsx_ProceedsFromSecuredBorrowingsRelatingToRoyaltyArrangements,monetaryItemType,bsx,"In the fourth quarter of 2019, we sold our rights to these royalties for $256 million in cash, included in Proceeds from royalty rights transfer in our consolidated statements of cash flows.",$256 million,MONEY,"In the fourth quarter of 2019, we sold our rights to these royalties for $256 million in cash, included in Proceeds from royalty rights transfer in our consolidated statements of cash flows.","['Proceeds from rights transfer', 'rights transfer in consolidated statements', 'consolidated statements of cash flows', 'rights transfer', 'consolidated statements', 'cash flows']","['cash', 0.8587784171104431, 'What is $256 million ?', 'cash']",cash,0.8587784171104431,What is $256 million ?,cash,Proceeds from royalty rights transfer
40,"The transaction price for the acquisition of BTG consisted of upfront cash in the aggregate amount of £3.312 billion (or $4.023 billion based on the exchange rate at closing on August 19, 2019) for the entire issued ordinary share capital of BTG, whereby BTG stockholders received 840 pence (or $10.20 based on the exchange rate at closing) in cash for each BTG share. The transaction price included $404 million of cash and cash equivalents acquired. We implemented our acquisition of BTG by way of a court sanctioned scheme of arrangement under Part 26 of the United Kingdom Companies Act 2006, as amended.",3.312,"['Payments to Acquire Businesses, Gross']",us-gaap_PaymentsToAcquireBusinessesGross,monetaryItemType,bsx,"The transaction price for the acquisition of BTG consisted of upfront cash in the aggregate amount of £3.312 billion (or $4.023 billion based on the exchange rate at closing on August 19, 2019) for the entire issued ordinary share capital of BTG, whereby BTG stockholders received 840 pence (or $10.20 based on the exchange rate at closing) in cash for each BTG share.",$£3.312 billion,MONEY,"The transaction price for the acquisition of BTG consisted of upfront cash in the aggregate amount of £3.312 billion or $4.023 billion based on the exchange rate at closing on August 19, 2019 for the entire issued ordinary share capital of BTG, whereby BTG stockholders received 840 pence or $10.20 based on the exchange rate at closing in cash for each BTG share.","['transaction price for acquisition', 'acquisition of BTG', 'aggregate amount', 'closing on August', 'closing for entire issued ordinary share capital', 'entire issued ordinary share capital of BTG', 'closing in cash', 'closing for BTG share', 'transaction price', 'upfront cash', 'aggregate amount', 'exchange rate', 'entire ordinary share capital', 'BTG stockholders', 'exchange rate', 'BTG share']","['upfront cash', 0.6142540574073792, 'What is $£3.312 billion ?', 'upfront cash']",upfront cash,0.6142540574073792,What is $£3.312 billion ?,upfront cash,Upfront cash
41,"The transaction price for the acquisition of BTG consisted of upfront cash in the aggregate amount of £3.312 billion (or $4.023 billion based on the exchange rate at closing on August 19, 2019) for the entire issued ordinary share capital of BTG, whereby BTG stockholders received 840 pence (or $10.20 based on the exchange rate at closing) in cash for each BTG share. The transaction price included $404 million of cash and cash equivalents acquired. We implemented our acquisition of BTG by way of a court sanctioned scheme of arrangement under Part 26 of the United Kingdom Companies Act 2006, as amended.",4.023,"['Payments to Acquire Businesses, Gross']",us-gaap_PaymentsToAcquireBusinessesGross,monetaryItemType,bsx,"The transaction price for the acquisition of BTG consisted of upfront cash in the aggregate amount of £3.312 billion (or $4.023 billion based on the exchange rate at closing on August 19, 2019) for the entire issued ordinary share capital of BTG, whereby BTG stockholders received 840 pence (or $10.20 based on the exchange rate at closing) in cash for each BTG share.",$4.023 billion,MONEY,"The transaction price for the acquisition of BTG consisted of upfront cash in the aggregate amount of £3.312 billion or $4.023 billion based on the exchange rate at closing on August 19, 2019 for the entire issued ordinary share capital of BTG, whereby BTG stockholders received 840 pence or $10.20 based on the exchange rate at closing in cash for each BTG share.","['transaction price for acquisition', 'acquisition of BTG', 'aggregate amount', 'closing on August', 'closing for entire issued ordinary share capital', 'entire issued ordinary share capital of BTG', 'closing in cash', 'closing for BTG share', 'transaction price', 'upfront cash', 'aggregate amount', 'exchange rate', 'entire ordinary share capital', 'BTG stockholders', 'exchange rate', 'BTG share']","['upfront cash', 0.46064871549606323, 'what is upfront cash ?', '£3.312 billion or $4.023 billion']",upfront cash,0.4606487154960632,what is upfront cash ?,£3.312 billion or $4.023 billion,Transaction price for acquisition
42,"The transaction price for the acquisition of BTG consisted of upfront cash in the aggregate amount of £3.312 billion (or $4.023 billion based on the exchange rate at closing on August 19, 2019) for the entire issued ordinary share capital of BTG, whereby BTG stockholders received 840 pence (or $10.20 based on the exchange rate at closing) in cash for each BTG share. The transaction price included $404 million of cash and cash equivalents acquired. We implemented our acquisition of BTG by way of a court sanctioned scheme of arrangement under Part 26 of the United Kingdom Companies Act 2006, as amended.",404,['Cash Acquired from Acquisition'],us-gaap_CashAcquiredFromAcquisition,monetaryItemType,bsx,The transaction price included $404 million of cash and cash equivalents acquired.,$404 million,MONEY,The transaction price included $404 million of cash and cash equivalents acquired.,['transaction price'],"['transaction price', 0.5562244653701782, 'what is transaction price ?', '$404 million']",transaction price,0.5562244653701782,what is transaction price ?,$404 million,Cash and cash equivalents acquired
43,"We recognized goodwill of $1.635 billion, which is attributable to the synergies expected to arise from the acquisition and revenue and cash flow projections associated with future technologies. We allocated $1.399 billion to our Peripheral Interventions reporting unit and $236 million to the Specialty Pharmaceuticals reporting unit. In 2020, we recorded Goodwill impairment charges of $73 million related to the execution of a definitive agreement to sell our Specialty Pharmaceuticals business. Refer to Note D-Goodwill and Other Intangible Assets for additional information.",1.635,"['Goodwill', 'Goodwill']",us-gaap_Goodwill,monetaryItemType,bsx,"We recognized goodwill of $1.635 billion, which is attributable to the synergies expected to arise from the acquisition and revenue and cash flow projections associated with future technologies.",$1.635 billion,MONEY,"We recognized goodwill of $1.635 billion, which is attributable to the synergies expected to arise from the acquisition and revenue and cash flow projections associated with future technologies.","['goodwill', 'future technologies']","['goodwill', 0.9488438367843628, 'What is $1.635 billion ?', 'goodwill']",goodwill,0.9488438367843628,What is $1.635 billion ?,goodwill,Recognized goodwill
44,"We recognized goodwill of $1.635 billion, which is attributable to the synergies expected to arise from the acquisition and revenue and cash flow projections associated with future technologies. We allocated $1.399 billion to our Peripheral Interventions reporting unit and $236 million to the Specialty Pharmaceuticals reporting unit. In 2020, we recorded Goodwill impairment charges of $73 million related to the execution of a definitive agreement to sell our Specialty Pharmaceuticals business. Refer to Note D-Goodwill and Other Intangible Assets for additional information.",1.399,"['Goodwill', 'Goodwill']",us-gaap_Goodwill,monetaryItemType,bsx,We allocated $1.399 billion to our Peripheral Interventions reporting unit and $236 million to the Specialty Pharmaceuticals reporting unit.,$1.399 billion,MONEY,We allocated $1.399 billion to our Peripheral Interventions reporting unit and $236 million to the Specialty Pharmaceuticals reporting unit.,"['Interventions reporting unit', 'reporting unit']","['', 0, '', '']",,0.0,,,"Peripheral Interventions reporting unit

Entity:
$236 million
Phrase:
Specialty Pharmaceuticals reporting unit"
45,"We recognized goodwill of $1.635 billion, which is attributable to the synergies expected to arise from the acquisition and revenue and cash flow projections associated with future technologies. We allocated $1.399 billion to our Peripheral Interventions reporting unit and $236 million to the Specialty Pharmaceuticals reporting unit. In 2020, we recorded Goodwill impairment charges of $73 million related to the execution of a definitive agreement to sell our Specialty Pharmaceuticals business. Refer to Note D-Goodwill and Other Intangible Assets for additional information.",236,"['Goodwill', 'Goodwill']",us-gaap_Goodwill,monetaryItemType,bsx,We allocated $1.399 billion to our Peripheral Interventions reporting unit and $236 million to the Specialty Pharmaceuticals reporting unit.,$236 million,MONEY,We allocated $1.399 billion to our Peripheral Interventions reporting unit and $236 million to the Specialty Pharmaceuticals reporting unit.,"['Interventions reporting unit', 'reporting unit']","['', 0, '', '']",,0.0,,,Specialty Pharmaceuticals reporting unit
46,"We recognized goodwill of $1.635 billion, which is attributable to the synergies expected to arise from the acquisition and revenue and cash flow projections associated with future technologies. We allocated $1.399 billion to our Peripheral Interventions reporting unit and $236 million to the Specialty Pharmaceuticals reporting unit. In 2020, we recorded Goodwill impairment charges of $73 million related to the execution of a definitive agreement to sell our Specialty Pharmaceuticals business. Refer to Note D-Goodwill and Other Intangible Assets for additional information.",73,['Goodwill impairment charges'],us-gaap_GoodwillImpairmentLoss,monetaryItemType,bsx,"In 2020, we recorded Goodwill impairment charges of  $73 million related to the execution of a definitive agreement to sell our Specialty Pharmaceuticals business.",$73 million,MONEY,"In 2020, we recorded Goodwill impairment charges of  $73 million related to the execution of a definitive agreement to sell our Specialty Pharmaceuticals business.","['impairment charges', 'execution of definitive agreement', 'impairment charges', 'definitive agreement', 'Pharmaceuticals business']","['', 0, '', '']",,0.0,,,Goodwill impairment charges
47,"On June 11, 2019, we completed our acquisition of Vertiflex, Inc. (Vertiflex), a privately held company which developed and commercialized the Superion™ Indirect Decompression System, a minimally invasive device used to improve physical function and reduce pain in patients with lumbar spinal stenosis (LSS). The transaction price consisted of an upfront cash payment of $465 million and contingent payments that are based on a percentage of Vertiflex sales growth in the first three years following the acquisition close. At the time of acquisition, we estimated the sales based contingent payments to be in a range of zero to $100 million; however, the payments are uncapped over the three year earn out period. Through December 31, 2021, we have made incremental payments of $20 million to the prior shareholders of Vertiflex in accordance with the terms of the agreement. Following the closing of the acquisition, we integrated the Vertiflex business into our Neuromodulation division.",465,"['Payments to Acquire Businesses, Gross']",us-gaap_PaymentsToAcquireBusinessesGross,monetaryItemType,bsx,The transaction price consisted of an upfront cash payment of $465 million and contingent payments that are based on a percentage of Vertiflex sales growth in the first three years following the acquisition close.,$465 million,MONEY,The transaction price consisted of an upfront cash payment of $465 million and contingent payments that are based on a percentage of Vertiflex sales growth in the first three years following the acquisition close.,"['upfront cash payment of payments', 'percentage of Vertiflex sales growth', 'transaction price', 'upfront cash payment', 'Vertiflex sales growth']","['upfront cash payment of payments', 0.9940615892410278, 'what is upfront cash payment of payments ?', '$465 million']",upfront cash payment of payments,0.9940615892410278,what is upfront cash payment of payments ?,$465 million,Transaction price
48,"On June 11, 2019, we completed our acquisition of Vertiflex, Inc. (Vertiflex), a privately held company which developed and commercialized the Superion™ Indirect Decompression System, a minimally invasive device used to improve physical function and reduce pain in patients with lumbar spinal stenosis (LSS). The transaction price consisted of an upfront cash payment of $465 million and contingent payments that are based on a percentage of Vertiflex sales growth in the first three years following the acquisition close. At the time of acquisition, we estimated the sales based contingent payments to be in a range of zero to $100 million; however, the payments are uncapped over the three year earn out period. Through December 31, 2021, we have made incremental payments of $20 million to the prior shareholders of Vertiflex in accordance with the terms of the agreement. Following the closing of the acquisition, we integrated the Vertiflex business into our Neuromodulation division.",zero,"['Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, Low']",us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueLow,monetaryItemType,bsx,"At the time of acquisition, we estimated the sales based contingent payments to be in a range of zero to $100 million; however, the payments are uncapped over the three year earn out period.",zero to $100 million,MONEY,"At the time of acquisition, we estimated the sales based contingent payments to be in a range of zero to $100 million; however, the payments are uncapped over the three year earn out period.","['time of acquisition', 'range', 'contingent payments']","['range', 0.8983384370803833, 'what is range ?', 'zero to $100 million']",range,0.8983384370803833,what is range ?,zero to $100 million,sales based contingent payments
49,"On June 11, 2019, we completed our acquisition of Vertiflex, Inc. (Vertiflex), a privately held company which developed and commercialized the Superion™ Indirect Decompression System, a minimally invasive device used to improve physical function and reduce pain in patients with lumbar spinal stenosis (LSS). The transaction price consisted of an upfront cash payment of $465 million and contingent payments that are based on a percentage of Vertiflex sales growth in the first three years following the acquisition close. At the time of acquisition, we estimated the sales based contingent payments to be in a range of zero to $100 million; however, the payments are uncapped over the three year earn out period. Through December 31, 2021, we have made incremental payments of $20 million to the prior shareholders of Vertiflex in accordance with the terms of the agreement. Following the closing of the acquisition, we integrated the Vertiflex business into our Neuromodulation division.",100,"['Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High']",us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh,monetaryItemType,bsx,"At the time of acquisition, we estimated the sales based contingent payments to be in a range of zero to $100 million; however, the payments are uncapped over the three year earn out period.",zero to $100 million,MONEY,"At the time of acquisition, we estimated the sales based contingent payments to be in a range of zero to $100 million; however, the payments are uncapped over the three year earn out period.","['time of acquisition', 'range', 'contingent payments']","['range', 0.8983384370803833, 'what is range ?', 'zero to $100 million']",range,0.8983384370803833,what is range ?,zero to $100 million,sales based contingent payments
